^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TQB2102

    i
    Associations
    News

    Trials

    Company:
    Sino Biopharm
    Drug class:
    Topoisomerase I inhibitor, HER2-targeted antibody-drug conjugate
    Related drugs:
    Associations
    News

    Trials

    Apply
    A Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer (TQB2102-III-01) (NCT06561607)
    Phase 3
    Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    Not yet recruiting
    Last update posted :
    08/20/2024
    Initiation :
    08/01/2024
    Primary completion :
    01/01/2027
    Completion :
    12/01/2028
    HER-2
    |
    capecitabine • albumin-bound paclitaxel • TQB2102
    A Study of TQB2102 for Injection in Patients With Recurrent/Metastatic Breast Cancer (NCT06115902)
    Phase 1
    Chia Tai Tianqing Pharmaceutical Group Nanjing ...
    Recruiting
    Last update posted :
    11/29/2023
    Initiation :
    11/17/2023
    Primary completion :
    12/01/2025
    Completion :
    12/01/2026
    HER-2
    |
    HER-2 expression
    |
    TQB2102
    Clinical Trial of the TQB2102 Injection in Patients With Advanced Cancers (NCT05735496)
    Phase 1
    Chia Tai Tianqing Pharmaceutical Group Nanjing ...
    Not yet recruiting
    Last update posted :
    02/27/2023
    Initiation :
    02/01/2023
    Primary completion :
    04/01/2024
    Completion :
    10/01/2024
    HER-2
    |
    HER-2 positive
    |
    TQB2102